本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Neumora Therapeutics, Inc.

1.04
-0.1000-8.77%
盤後1.060.0200+1.92%19:56 EDT
成交量:188.08萬
成交額:199.87萬
市值:1.96億
市盈率:-0.85
高:1.16
開:1.16
低:1.02
收:1.14
52周最高:3.65
52周最低:0.8302
股本:1.88億
流通股本:1.16億
量比:3.27
換手率:1.62%
股息:- -
股息率:- -
每股收益(TTM):-1.2237
每股收益(LYR):-1.4501
淨資產收益率:-187.11%
總資產收益率:-73.85%
市淨率:4.39
市盈率(LYR):-0.72

資料載入中...

公司資料

公司名字:
Neumora Therapeutics, Inc.
交易所:
NASDAQ
成立時間:
2019
員工人數:
63
公司地址:
260 Arsenal Place,Suite 1,Watertown,Massachusetts,United States
郵編:
02472
電話:
傳真:
- -
簡介:
Neumora Therapeutics, Inc.最初於2019年11月在特拉華州註冊成立。該公司是一家臨床階段的生物製藥公司,旨在通過提出下一代腦滲透化學新療法,為患者提供更好的治療結果和生活質量,以應對其這一代人面臨的最大醫療挑戰。該公司的治療管道目前包括針對各種服務不足的流行疾病的新作用機制的項目。

董事

名稱
職位
Henry O. Gosebruch
President, Chief Executive Officer and Director
Paul L. Berns
Executive Chairman
Alaa Halawa
Director
David Piacquad
Director
Kristina Burow
Director
Matthew Fust
Director
Maykin Ho
Director

股東

名稱
職位
Henry O. Gosebruch
President, Chief Executive Officer and Director
Carol Suh
Chief Operating Officer
Joshua Pinto
Chief Financial Officer
Daljit Singh Aurora
Chief Strategy Officer
Lori Houle
Chief Quality Officer
Maryjo Chamberlain Tharp
Chief Business Officer
Michael Gold
Chief Medical Officer
Nicholas Brandon
Chief Scientific Officer
Paul L. Berns
Executive Chairman
Raj Manchanda
Chief Technical Operations Officer
Robert Lenz
Head of Research and Development